Lonafarnib for Chronic Hepatitis D
关键词
抽象
描述
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. We propose to treat between 12 and 14 patients with chronic delta hepatitis using the farnesyltransferase inhibitor (FTI) lonafarnib for a duration of twenty-eight days. Farnesyltransferase inhibitors have not been used in the therapy of delta hepatitis. Patients with HBsAg and HDV RNA in serum, elevated aminotransferases, or moderate-to-severe chronic hepatitis and HDV antigen on liver biopsy will be enrolled. Before receiving therapy, patients will be monitored for at least three months with regular testing for alanine aminotransferase (ALT) levels and will undergo Clinical Center admission for medical evaluation and percutaneous liver biopsy. Two dosing groups of lonafarnib will be assessed, with a placebo cohort in each group. At each clinic visit, patients will be questioned about side effects and symptoms, undergo focused physical examination, and have blood drawn for complete blood counts, HDV RNA, and routine liver tests (including ALT, AST, alkaline phosphatase, direct and total bilirubin, and albumin). At two-week intervals, for a period of 28 days, patients will also be tested for HBsAg, anti-HBs, HBV DNA, and prothrombin time. At the end of 28 days of treatment, patients will undergo repeat physical examination, assessment of symptoms (using a symptom scale questionnaire), complete blood counts, routine liver tests, and hepatitis B and D viral markers. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after 28 days of lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the 4 week duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib (which will be carefully defined). This study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of two dose levels of lonafarnib, a farnesyltransferase inhibitor.
日期
最后验证: | 06/30/2016 |
首次提交: | 12/15/2011 |
提交的预估入学人数: | 12/15/2011 |
首次发布: | 12/19/2011 |
上次提交的更新: | 07/17/2016 |
最近更新发布: | 08/30/2016 |
首次提交结果的日期: | 04/27/2016 |
首次提交质量检查结果的日期: | 07/17/2016 |
首次发布结果的日期: | 08/30/2016 |
实际学习开始日期: | 11/30/2011 |
预计主要完成日期: | 03/31/2015 |
预计完成日期: | 03/31/2015 |
状况或疾病
干预/治疗
Drug: Lonafarnib
Other: Placebo
相
手臂组
臂 | 干预/治疗 |
---|---|
Placebo Comparator: Placebo Placebo control | Other: Placebo Placebo control |
Experimental: Group 1 lonafarnib 100mg | |
Experimental: Group 2 lonafarnib 200mg |
资格标准
有资格学习的年龄 | 18 Years 至 18 Years |
有资格学习的性别 | All |
接受健康志愿者 | 是 |
标准 | - INCLUSION CRITERIA: 1. Age 18 years or above, male or female. 2. Serum alanine or aspartate aminotransferase activities above the upper limit of normal (ALT > 41 or AST > 31 U/L) on an average of three determinations taken during the previous 6 months. The mean of the three determinations will be defined as baseline levels. 3. Presence of anti-HDV in serum. 4. Evidence of chronic hepatitis on liver biopsy done within the previous 12 months with a necroinflammatory score in histology activity index of at least 5 (out of a maximum of 18) and at least 1 for hepatic fibrosis (out of a maximum of 6). 5. Presence of HDV antigen in liver tissue or HDV RNA in serum. 6. Written informed consent. EXCLUSION CRITERIA: 1. Decompensated liver disease, defined by bilirubin > 4mg/dL, albumin < 3.0 gm/dL, prothrombin time > 2 sec prolonged, or history of bleeding esophageal varices, ascites or hepatic encephalopathy. Laboratory abnormalities that are not thought to be due to liver disease may not necessarily require exclusion. Patients with ALT levels greater than 1000 U/L (> 25 times ULN) will not be enrolled but may be followed until three determinations are below this level. 2. Pregnancy or inability to practice adequate contraception, in women of childbearing potential or in spouses of such women. Adequate contraception is defined as vasectomy in men, tubal ligation in women, or use of two barrier methods such as condoms and spermicide combination, birth control pills, an intrauterine device, Depo-Provera, or Norplant. 3. Significant systemic or major illnesses other than liver disease, including, but not limited to, congestive heart failure, renal failure (eGFR < 50 ml/min), organ transplantation, serious psychiatric disease or depression (only if felt to be at high risk by the NIH psychiatric consultation service), and active coronary artery disease. 4. Systemic immunosuppressive therapy within the previous 2 months. 5. Evidence of another form of liver disease in addition to viral hepatitis (for example autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson disease, alcoholic liver disease, nonalcoholic steatohepatitis (but not steatosis), hemochromatosis, or alpha-1-antitrypsin deficiency). 6. Active substance abuse, such as alcohol, inhaled or injection drugs within the previous year. 7. Evidence of hepatocellular carcinoma. 8. Evidence of concurrent hepatitis C infection with positive serum HCV RNA. 9. Any experimental therapy apart from pegylated interferon within 6 months prior to enrollment. 10. Diagnosis of malignancy in the five years prior to the enrollment with exception granted to superficial dermatologic malignancies. 11. Evidence of HIV co-infection; HIV (Omega) antibody positivity on serum testing. 12. Concurrent usage of statins as these drugs inhibit mevalonate synthesis which reduces protein prenylation. 13. Concurrent usage of moderate and strong CYP3A inhibitors and inducers. 14. Inability to understand or sign informed consent. 15. Any other condition, which in the opinion of the investigators would impede the patient s participation or compliance in the study. |
结果
主要结果指标
1. Change in Quantitative Serum HDV RNA Levels After 28 Days of Lonafarnib Therapy. [28 days]
次要成果指标
1. ALT Levels [7 months]